This inventor holds 2 USPTO granted patents. Top assignee: Adaptimmune Limited. Active years: 2018-2020.
Company Filing History:
Years Active: 2018-2020
Title: Kathrin Skibbe: Innovator in Cancer Treatment
Introduction
Kathrin Skibbe is a prominent inventor based in Abingdon, GB. She has made significant contributions to the field of cancer treatment through her innovative work on modified T cells. With a total of 2 patents, her research focuses on enhancing the efficacy of immunotherapy.
Latest Patents
Kathrin's latest patents include groundbreaking inventions related to T cells with increased immunosuppression resistance. This invention pertains to the treatment of cancer in individuals by administering a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof. These T cells are designed to bind specifically to cancer cells, providing a targeted approach to cancer therapy. The patents also cover populations of modified T cells, methods of producing these populations, and pharmaceutical compositions for treatment.
Career Highlights
Kathrin Skibbe is currently associated with Adaptimmune Limited, where she continues to advance her research in immunotherapy. Her work has garnered attention for its potential to revolutionize cancer treatment and improve patient outcomes.
Collaborations
Kathrin collaborates with various professionals in her field, including her coworker Bruno Laugel. Their combined expertise contributes to the innovative projects at Adaptimmune Limited.
Conclusion
Kathrin Skibbe's contributions to cancer treatment through her patented inventions highlight her role as a leading innovator in the field. Her work promises to enhance the effectiveness of immunotherapy and offers hope for improved cancer treatments in the future.